Discovery and characterization of novel mutant FLT3 kinase inhibitors.
For a subpopulation of acute myeloid leukemia (AML) patients, the constitutively activated tyrosine kinase, mutant FLT3, has emerged as a promising target for therapy. The development of drug resistance, however, is a growing concern for mutant FLT3 inhibitors, such as PKC412. Potential therapeutic benefit can arise from the combination of two structurally diverse inhibitors that target-but bind differently to-the same protein or from two inhibitors with completely different mechanisms of action. Thus, there is a need for identification and development of novel FLT3 inhibitors that have the ability to positively combine with PKC412 or standard chemotherapeutic agents used to treat AML as a way to suppress the development of drug resistance and consequently prolong disease remission. Here, we report the effects of the novel type II ATP-competitive inhibitors, HG-7-85-01 and HG-7-86-01, which potently and selectively target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3-ITD or FLT3 kinase domain point mutants via induction of apoptosis and cell cycle inhibition. Antileukemic activity of HG-7-85-01 was shown in vivo to be comparable with that observed with PKC412 in a bioluminescence assay using NCr nude mice harboring Ba/F3-FLT3-ITD-luc+ cells. HG-7-85-01 was also observed to override PKC412 resistance. Finally, HG-7-85-01 and HG-7-86-01 synergized with PKC412 and standard chemotherapeutic agents against mutant PKC412-sensitive and some PKC412-resistant, FLT3-positive cells. Thus, we present a structurally novel class of FLT3 inhibitors that warrants consideration for clinical testing against drug-resistant disease in AML patients.
Weisberg
Ellen
E
Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. ellen_weisberg@dfci.harvard.edu
Choi
Hwan Geun
HG
Barrett
Rosemary
R
Zhou
Wenjun
W
Zhang
Jianming
J
Ray
Arghya
A
Nelson
Erik A
EA
Jiang
Jingrui
J
Moreno
Daisy
D
Stone
Richard
R
Galinsky
Ilene
I
Fox
Edward
E
Adamia
Sophia
S
Kung
Andrew L
AL
Gray
Nathanael S
NS
Griffin
James D
JD
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D006801:Humans; D015151:Immunoblotting; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D058990:Molecular Targeted Therapy; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism
D047428:Protein Kinase Inhibitors; D051941:fms-Like Tyrosine Kinase 3
Cancer Cell. 2005 Feb;7(2):129-41
15710326
Blood. 2010 May 27;115(21):4206-16
20299508
Blood. 2001 Apr 15;97(8):2434-9
11290608
Blood. 2006 Oct 1;108(7):2332-8
16772610
Blood. 2009 Oct 1;114(14):2984-92
19654408
Nat Biotechnol. 2008 Jan;26(1):127-32
18183025
Blood. 2005 Jan 1;105(1):335-40
15345593
Drug Resist Updat. 2009 Jun;12(3):81-9
19467916
Cancer Cell. 2003 Feb;3(2):173-83
12620411
Med Pediatr Oncol. 1999 Dec;33(6):525-9
10573574
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93
16203792
N Engl J Med. 2003 Mar 27;348(13):1201-14
12660384
Leukemia. 1997 Sep;11(9):1469-77
9305600
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3395-400
15705718
Mol Cancer Ther. 2007 Jul;6(7):1951-61
17620426
Nat Rev Cancer. 2003 Sep;3(9):650-65
12951584
Blood. 2004 Sep 15;104(6):1855-8
15178581
Cancer Cell. 2002 Aug;2(2):117-25
12204532
Nat Chem Biol. 2006 Jul;2(7):358-64
16783341
Leukemia. 1996 Dec;10(12):1911-8
8946930
Clin Lab Sci. 2005 Winter;18(1):28-37
15747784
Cancer Cell. 2002 Jun;1(5):433-43
12124173
Leukemia. 1998 Sep;12(9):1333-7
9737679
Cancer Cell. 2007 Dec;12(6):501-13
18068628
Blood. 2006 Jan 1;107(1):293-300
16150941
Adv Enzyme Regul. 1984;22:27-55
6382953
Blood. 2008 Dec 15;112(13):5161-70
18820131
Leukemia. 2000 Apr;14(4):675-83
10764154
IDrugs. 2008 Jan;11(1):46-56
18175263
Blood. 2002 Jan 1;99(1):310-8
11756186
Leukemia. 1997 Sep;11(9):1442-6
9305595
J Biol Chem. 2003 Feb 14;278(7):5148-55
12435730
Cancer Res. 2004 Sep 15;64(18):6385-9
15374944